The benefit was seen with atezolizumab in the phase III IMpower110 trial for PD-L1 ≥ 1% NSCLC, although in an updated analysis, the OS benefit was no longer statistically significant [8,33]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.